Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial

C Bachert, AR Sousa, VJ Lund, GK Scadding… - Journal of Allergy and …, 2017 - Elsevier
Background Patients with eosinophilic nasal polyposis frequently require surgery, and
recurrence rates are high. Objective We sought to assess the efficacy and safety of
mepolizumab versus placebo for severe bilateral nasal polyposis. Methods This
randomized, double-blind, placebo-controlled trial recruited patients aged 18 to 70 years
with recurrent nasal polyposis requiring surgery. Patients received 750 mg of intravenous
mepolizumab or placebo every 4 weeks for a total of 6 doses in addition to daily topical …